COL4A3

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Mittwoch, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

Alport Syndrome Market to Witness Upsurge in Growth at a Massive CAGR of 69% by 2034 | DelveInsight

Retrieved on: 
Mittwoch, April 17, 2024
USD, Urine, ACE, Finerenone, ESRD, Kidney, Otorhinolaryngology, Nephrotoxicity, Mutation, Hearing, Diagnosis, Glomerular filtration rate, Hearing loss, Blood, Swelling, Proteinuria, Kidney failure, Cochlea, Alport syndrome, Nephrology, EU4, GFR, ADAS, Heredity, Research, Genetic counseling, Kidney disease, Novartis, ARAS, Ophthalmology, COL4A4, Patient, Kidney transplantation, LAS, Dialysis, DSM-IV codes, COL4A3, Quality of life, Genetic disorder, Gene, Pharmaceutical industry

LAS VEGAS, April 17, 2024 /PRNewswire/ -- DelveInsight's Alport Syndrome Market Insights report includes a comprehensive understanding of current treatment practices, Alport syndrome emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Points: 
  • Leading Alport syndrome companies such as Eloxx Pharmaceuticals, Chinook Therapeutics (A Novartis company), Bayer, Calliditas Therapeutics, Evotec, and others are developing novel Alport syndrome drugs that can be available in the Alport syndrome market in the coming years.
  • The disorder manifests in different forms such as autosomal recessive Alport syndrome (ARAS), X-linked Alport syndrome (XLAS), and autosomal dominant Alport syndrome (ADAS).
  • The X-linked Alport syndrome (XLAS) is the most prevalent subtype of Alport syndrome with around 11K cases in 2023 in the US while autosomal dominant Alport syndrome (ADAS) is the least prevalent subtype of Alport syndrome.
  • To know more about Alport syndrome treatment guidelines, visit @ Alport Syndrome Management

Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update

Retrieved on: 
Montag, April 3, 2023
COL7, Polyp, Collagen, Skin, Drug development, Hearing loss, Familial adenomatous polyposis, Survival, Clinical trial, Mutation, American Society of Nephrology, G&A, Cystic fibrosis, FAP, Fibroblast, RNA, Alport syndrome, Trial of the century, ASN, Cancer, Proteinuria, COL4A5, Investigational New Drug, Genetic disorder, Patient, COL4A3, Keratinocyte, Kidney, Adenoma, Cystic Fibrosis Foundation, COL, Growth, Epidermolysis bullosa dystrophica, APC, Rare, R, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, COL4A4, Society, Conference, Food, Kidney disease, Pharmaceutical industry, Cryptocurrency, RDEB, Alport

WATERTOWN, Mass., April 03, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today reported its financial results for the three months ended December 31, 2022 and provided a business update.

Key Points: 
  • Alport syndrome is a rare genetic disorder characterized by kidney disease with high levels of proteinuria, hearing loss and eye abnormalities.
  • Eloxx presented a poster highlighting the activity of ELX-02 across a range of COL4A5 mutations in preclinical models at the American Society of Nephrology (ASN) Kidney Week 2022 Conference in early November 2022.
  • Recent preclinical results demonstrated read-through activity of ZKN-013 in multiple COL7 genotypes across multiple RDEB patient derived fibroblasts and keratinocytes.
  • R&D expenses were $3.3 million for the three months ended December 31, 2022, which includes $0.3 million in stock-based compensation.

Eloxx Pharmaceuticals Announces Opening of Clinical Trial Sites for Phase 2 Study of ELX-02 for the Treatment of Alport Syndrome

Retrieved on: 
Dienstag, November 1, 2022
RNA transfection, RNA, Plasma, RMAS, Science, CF, Mutation, SEC, Clinical trial, Cancer, GLOBE, Patient, Royal commission, Research, Eukaryotic ribosome, COVID-19, Allele, Disease, COL4A3, File, European Commission, Degenerative disease, Cystic fibrosis, Proteinuria, Kidney disease, Safety, Genetic disorder, Patent, Judgement, COL4A5, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Private Securities Litigation Reform Act, Polycystic kidney disease, Hearing loss, FDA, Kidney, Food, Fast Track, Alport syndrome, Autosome, Forward-looking statement, Gene, COL4A4, Orphan, Pharmaceutical industry, Alport

Additional sites are expected to be opened and actively recruiting Alport patients in the coming weeks, said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.

Key Points: 
  • Additional sites are expected to be opened and actively recruiting Alport patients in the coming weeks, said Sumit Aggarwal, President and Chief Executive Officer of Eloxx.
  • Alport patients with nonsense mutations have significantly worse clinical outcomes than other Alport patients and have no disease modifying treatment options.
  • This proof-of-concept clinical trial will include up to eight Alport syndrome patients with nonsense mutations in the second half of 2022.
  • Approximately 6% to 7% of Alport syndrome patients, or approximately 9,400 to 12,750 individuals, are estimated to have nonsense mutations.

Eloxx Pharmaceuticals Announces New Development Program for ELX-02 for the Treatment of Alport Syndrome

Retrieved on: 
Mittwoch, März 30, 2022
Disease, Autosome, Private Securities Litigation Reform Act, COL4A4, Plasma, Population, NASDAQ, Degenerative disease, COL4A3, Patent, Polycystic kidney disease, Eukaryotic ribosome, Forward-looking statement, Clinical trial, Kidney, Hearing loss, Mutation, Judgement, Proteinuria, SEC, Research, Program, Alport syndrome, Patient, Cancer, Kidney disease, Allele, RNA, Cystic fibrosis, Safety, RNA transfection, COVID-19, GLOBE, Gene, Genetic disorder, Science, RMAS, File, Pharmaceutical industry, COL4A5, Alport

WATERTOWN, Mass., March 30, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced it has expanded the ELX-02 development program to include the treatment of Alport syndrome, a rare kidney disease. Clinical testing of ELX-02 in Alport syndrome is expected to initiate in the second half of 2022, with topline results expected in the first half of 2023.

Key Points: 
  • Clinical testing of ELX-02 in Alport syndrome is expected to initiate in the second half of 2022, with topline results expected in the first half of 2023.
  • Approximately 6% to 7% of Alport syndrome patients, or approximately 9,400 to 12,750 individuals, are estimated to have nonsense mutations.
  • These patients have significantly worse clinical outcomes than other Alport patients and have no disease modifying treatment options.
  • Eloxx intends to initiate a proof-of-concept clinical trial in up to eight Alport syndrome patients with nonsense mutations in the second half of 2022.